CoreWeave's Risks Seen as Priced-In — Market Talk

The risks associated with CoreWeave are real, but they are "more than adequately priced-in" at the stock's recent valuation of around three times 2027 revenue, UBS analysts write in a note, initiating coverage with a buy rating. They identify several risks hanging over the stock: the leverage neede…